Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336603 · ClinicalTrials.gov registry record · Phase 4
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
A Phase 4 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT06336603 is a Phase 4 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 20 participants.
The verdict
NCT06336603, a Phase 4 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.
Interventions
- DRUG Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06336603
The ClinicalTrials.gov registry entry for NCT06336603 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Winlevi (clascoterone) 1% & Adapalene 0.3% gel is the first listed.
NCT06336603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06336603 about?
NCT06336603 is a clinical study titled "A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne". Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.
What is the current status of trial NCT06336603?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-11-15. Estimated completion is 2024-10-29.
What interventions are being tested in trial NCT06336603?
The interventions under investigation include: Winlevi (clascoterone) 1% & Adapalene 0.3% gel (DRUG).
Who is sponsoring clinical trial NCT06336603?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.